ADMA
ADMA Biologics
2.0%
0.0%
$9.94
$9.94
Why This Position Exists
ADMA Biologics is classified as price-below-value with MEDIUM confidence at $9.94, reflecting a 29% decline from pre-short-report levels. The prediction ensemble collectively suggests the stock has overcorrected for fraud risk: SEC investigation probability is just 16% with 96% model agreement, CEO remains a net buyer (77% probability of continuing), and Q1 2026 revenue is expected above $130M (75% probability), which would largely refute the channel stuffing allegation. The ensemble identifies genuine working capital concerns (DSO above 90 days at 57%) but distinguishes these from fraud, supporting the thesis that the market overweights the most extreme short seller claims relative to the more likely outcome of legitimate growth with manageable receivables dynamics.
Trigger: Initial thesis assessment for ADMA generated 2026-04-09 from analysis run ADMA-2026-04-09. Multi-lens analysis following Culper Research short report examined accounting integrity, revenue durability, insider behavior, and stress scenarios. Classification driven by ensemble consensus that fraud risk is overpriced while fundamental ASCENIV growth trajectory remains intact.
Key Market Signals
Committee Verdict
The Portfolio Analyst identified a post-short-report overcorrection thesis where the ensemble strongly discounts fraud risk (SEC investigation at 16% with 96% agreement, CEO net selling at only 23%) while expecting Q1 revenue to confirm organic growth (75% probability above $130M). The Risk Manager's Kelly formula produced 2.05%, barely clearing the 2% minimum, and confirmed all portfolio constraints are met with cash remaining at 24.1% (well above the 5% floor). The Devil's Advocate raised two high-severity concerns — the acknowledged information gap on the full Culper Research report and the HIGH-weight DSO market leaning unfavorable at 57% — assessed overall as 'mixed.' Both concerns are legitimate but do not invalidate the thesis: the information gap is partially compensated by independent triangulation (KPMG audit, CEO buying, time elapsed without SEC action), and the DSO question asks about H1 specifically while management guides to H2 normalization. At 2% weight (~$2,000), the position is immaterial to NAV and the minimum sizing adequately reflects the borderline quantitative conviction. The Biotechnology sector diversification benefit adds a new sector to the portfolio. Opening at minimum size allows participation in the Q1 revenue catalyst while limiting downside if the working capital concerns prove more serious than the ensemble expects.
Devil's Advocate
mixedThe thesis has genuine strengths: high model agreement (92-96%) across all 7 markets, strong de-escalation signals on fraud risk (SEC at 16%, CEO buying at 77%), and a validated product with real clinical differentiation. However, three factors prevent a 'thesis-robust' classification: (1) the acknowledged information gap on the full short seller report creates unquantified risk, (2) the single HIGH-weight market leans unfavorable with an 'escalate' implication, and (3) the single-product and customer concentration risks are structural rather than temporary. At minimum Kelly sizing (2%), the capital at risk is immaterial, which provides adequate buffer for these concerns. The thesis is not fragile — the fraud case appears genuinely weak — but the working capital and concentration concerns are legitimate and unresolved.
Notable Dissent
Devil's Advocate raised two high-severity concerns that the committee acknowledges as legitimate but non-blocking. First, the full Culper Research short report was not obtained for analysis, creating an information asymmetry on the most extreme allegations — this is a real gap but is partially mitigated by the ensemble's triangulation from multiple independent data sources. Second, the single HIGH-weight market (DSO) leans unfavorable with an 'escalate' implication at 57% — this is the strongest quantitative argument against the position, but the 57% probability for an H1-specific question is consistent with management's H2 normalization timeline rather than a structural failure. The committee approves at minimum sizing, reflecting that the fraud thesis appears genuinely weak while the working capital concerns are real but manageable.
Monitoring Triggers
• Re-evaluate on Q1 2026 earnings release (expected May 2026) — the definitive near-term catalyst for channel stuffing thesis resolution
• Re-evaluate if SEC formal investigation is disclosed — would trigger immediate reassessment and likely closure
• Re-evaluate if CEO Grossman becomes a net seller of ADMA shares — undermines the strongest governance counter-signal
• Re-evaluate if Q2 2026 DSO shows no improvement trajectory from Q1 levels
• Mandatory review if position return drops below -15%
• Re-evaluate if a follow-up short seller report is published with new evidence
Position Details
Apr 9, 2026
201
price-below-value
MEDIUM
Healthcare
1
Kelly Sizing Breakdown
EDGE
ODDS
KELLY
Trade History
| Date | Action | Shares | Price | Weight | Rationale |
|---|---|---|---|---|---|
| Apr 9, 2026 | OPEN | 201 | $9.94 | 0.0% → 2.0% | Committee approved OPEN at 2.0% weight — price-below-value (MEDIUM confidence) |
Full Committee Transcripts (1)
Complete 4-step discourse records — expand each step to see the full reasoning from analyst, risk manager, devil's advocate, and committee chair.